Global Ankylosing Spondylitis (Bekhterev's Disease) Therapeutcis Pipeline Review 2014 (25 Companies & 16 Drug Profiles)
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zqc5nl/ankylosing) has announced the addition of the "Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Merck & Co., Inc. - Piramal Enterprises Limited - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - Sandoz Inc. - Celgene Corporation - Panacea Biotec Limited - Viropro Inc. - Avesthagen Limited - Shanghai Celgen Bio-Pharmaceutical Co., Ltd. - Biosidus S.A. - Genor BioPharma Co., Ltd. - Aprogen, Inc. - Inbiopro Solutions Pvt. Ltd. - Curaxys, S.L. - Innovent Biologics, Inc. - PanPharmaceuticals USA, Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd - Pharmapraxis Drug Profiles - BI-655066 - IBI-303 - IBPM-004-AM - IBPM-005-IX - INV-17 - ND-007 - P-979 - adalimumab biosimilar - apremilast - etanercept biosimilar - etoricoxib - infliximab biosimilar - infliximab biosmiliar - ixekizumab - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/zqc5nl/ankylosing
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
PR Newswire Europe - Mon Feb 25, 9:03AM CST
Viropro, Inc. and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.